• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LifeVantage Announces Preliminary Second Quarter Revenue Results and Raises Fiscal 2025 Revenue Guidance

    1/8/25 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFVN alert in real time by email

    SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced preliminary revenue results for the second quarter ended December 31, 2024, and raised its fiscal 2025 revenue guidance.  

    Preliminary Second Quarter Fiscal 2025 Highlights:

    • Revenue of approximately $67.5 million, an increase of 31% from the prior year period, and up 43% sequentially from the first fiscal quarter
    • Active Account growth in the Americas of 22.7% in comparison to the prior year period, and up 25.4% sequentially from the first fiscal quarter
    • Active Account growth of 12.1% globally in comparison to the prior year period, and up 18.5% sequentially from the first fiscal quarter

    Fiscal 2025 Guidance:

    • The Company now expects revenue in the range of $235 million to $245 million in fiscal 2025 compared to prior revenue guidance of $200 million to $210 million

    "Second quarter revenue results were exceptional, reflecting strong sales of the MindBody GLP-1 System™ we launched in October in the United States along with outstanding execution by our team to quickly ramp supply chain and fulfillment capacity to meet the robust demand," said Steve Fife, President and CEO of LifeVantage. "We also saw significant growth in Active Accounts driven by the highest number of enrollments in a quarter since third quarter of fiscal 2019. We look forward to providing more details, including our profitability outlook, when we report our fiscal Q2 results in early February. With business momentum strong, we remain well positioned to deliver significant growth and shareholder value."

    About LifeVantage Corporation

    LifeVantage Corporation® (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the newest MindBody GLP-1 System™, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System™, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own sales business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.

    Cautionary Note Regarding Forward Looking Statements

    This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," "may be," and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements we make regarding expected financial performance, including financial guidance and projections relating to expected revenue and margins, expected demand from our independent Consultants and Customers, executing against and the benefits of our key initiatives, and expected future growth and expansion, including geographic and product expansion. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, our ability to properly motivate and incentivize sales from our independent Consultants, our ability to retain existing Customers and independent Consultants or attract additional Customers and independent Consultants, our dependence on a few products for a majority of our revenue, our dependency on third parties to manufacture our products, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission (the "SEC"). The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

    Investor Relations Contact:

    Reed Anderson, ICR

    (646) 277-1260

    [email protected]



    Primary Logo

    Get the next $LFVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFVN

    DatePrice TargetRatingAnalyst
    1/14/2025$35.00Buy
    Craig Hallum
    12/19/2024$26.00Buy
    Lake Street
    More analyst ratings

    $LFVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LifeVantage Inspires with 'Breakthrough' Announcements at 2026 Momentum Academy in Las Vegas

    SALT LAKE CITY, April 20, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, successfully concluded its three-day Momentum Academy event at Planet Hollywood Resort and Casino in Las Vegas, Nevada. Centered on the theme of "Breakthrough," the event brought together LifeVantage independent Consultants from across the country for an immersive experience focused on education, connection, and business growth. Attendees gained practical insights through leadership and product training, along with simple, actionable strategies to grow with greater clarity and con

    4/20/26 8:00:00 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Appointing Terrence Moorehead as Chief Executive Officer

    SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) ("LifeVantage" or the "Company"), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Terrence Moorehead as the Company's new President and Chief Executive Officer and as a member of the Board of Directors (the "Board"), effective August 5, 2026. Mr. Moorehead is expected to commence employment with LifeVantage following the completion of his contractual commitments with his prior employer. Mr. Moorehead brings more than 25 years of leadership experience revitalizing brands, accelerating customer gr

    4/16/26 5:15:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Participate in Water Tower Research Insights Conference on Wednesday, April 15, 2026

    SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer, Kristen Cunningham, Chief Sales Officer, and Lisa Barnes, Vice President Research & Development and Regulatory, will participate in the upcoming Water Tower Research Insights Conference on Wednesday, April 15, 2026. The webcast of the presentation will begin at approximately 12:30 p.m. Eastern Time on Wednesday, April 15, 2026. The event is open access for all investors and interested parties can register direc

    4/9/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dayton Judd bought $152,422 worth of shares (33,197 units at $4.59), increasing direct ownership by 70% to 80,359 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    3/2/26 6:44:28 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $20,651 worth of shares (3,955 units at $5.22), increasing direct ownership by 3% to 135,508 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    2/11/26 4:32:08 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis Darwin bought $5,265 worth of shares (805 units at $6.54), increasing direct ownership by 0.62% to 131,553 units (SEC Form 4)

    4 - Lifevantage Corp (0000849146) (Issuer)

    12/17/25 4:23:51 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Cunningham Kristen

    4 - Lifevantage Corp (0000849146) (Issuer)

    4/3/26 4:05:06 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Neufeld Alissa

    4 - Lifevantage Corp (0000849146) (Issuer)

    4/3/26 4:05:07 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Aure Carl

    4 - Lifevantage Corp (0000849146) (Issuer)

    4/3/26 4:05:06 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    SEC Filings

    View All

    Lifevantage Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Lifevantage Corp (0000849146) (Filer)

    4/16/26 5:15:15 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Lifevantage Corporation

    EFFECT - Lifevantage Corp (0000849146) (Filer)

    3/23/26 12:15:12 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Lifevantage Corporation

    S-3 - Lifevantage Corp (0000849146) (Filer)

    3/10/26 4:27:58 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Leadership Updates

    Live Leadership Updates

    View All

    LifeVantage Appointing Terrence Moorehead as Chief Executive Officer

    SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) ("LifeVantage" or the "Company"), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Terrence Moorehead as the Company's new President and Chief Executive Officer and as a member of the Board of Directors (the "Board"), effective August 5, 2026. Mr. Moorehead is expected to commence employment with LifeVantage following the completion of his contractual commitments with his prior employer. Mr. Moorehead brings more than 25 years of leadership experience revitalizing brands, accelerating customer gr

    4/16/26 5:15:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Appoints Seasoned Technology Executive Mike Edwards as Chief Technology Officer to Drive Digital Innovation

    SALT LAKE CITY, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the addition of Mike Edwards as Chief Technology Officer. Edwards brings more than 25 years of experience as an accomplished senior executive specializing in technology leadership and enterprise transformation. "Mike is a strategic leader with a strong track record of translating technological innovation into measurable business impact and we are delighted to have him join the LifeVantage team," said Steve Fife, President and CEO of LifeVantage. "His expertise in eCo

    1/7/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced it has entered into a definitive agreement to acquire LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions.* LoveBiome has established itself as a leader in the emerging microbiome health sector, focusing on the critical connection between gut health and overall wellness. The company's innovative P84 product takes the guesswork out of gut health, regulating, repairing, and restoring the gut and microbiome th

    9/3/25 5:00:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Financials

    Live finance-specific insights

    View All

    LifeVantage Declares Quarterly Dividend

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid March 16, 2026 to all stockholders of record at the close of business on March 2, 2026. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products w

    2/4/26 4:06:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2026

    SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2025. Second Quarter Fiscal 2026 Summary*: Revenue was $48.9 million, a decrease of 27.8% from the prior year period. Revenue was up 2.9% sequentially from the first quarter.Revenue in the Americas decreased 32.6%, and revenue in Asia/Pacific & Europe decreased 2.1%.Net income per diluted share was $0.02, versus $0.19 per diluted share a year ago;Adjusted earnings per diluted share was $0.15, compared

    2/4/26 4:04:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeVantage to Announce Second Quarter Fiscal Year 2026 Results on February 4, 2026

    SALT LAKE CITY, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its second quarter ended December 31, 2025, after the stock market closes on Wednesday, February 4, 2026. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hour

    1/21/26 4:05:00 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lifevantage Corporation

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    7/31/24 8:07:09 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:29:36 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lifevantage Corporation (Amendment)

    SC 13D/A - Lifevantage Corp (0000849146) (Subject)

    2/15/24 4:27:16 PM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Lifevantage with a new price target

    Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

    1/14/25 8:36:52 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Lifevantage with a new price target

    Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

    12/19/24 8:39:43 AM ET
    $LFVN
    Biotechnology: Pharmaceutical Preparations
    Health Care